Trenchant BioSystems and Invetech confirmed a development partnership to commercialize the AutoCell platform, a fully automated cell‑and‑gene therapy (CGT) manufacturing system designed for point‑of‑care use. Company data indicate the platform can reduce or eliminate some ex vivo expansion steps and manufacture T cells from a single whole‑blood draw, enabling distributed production models. Invetech will provide engineering and manufacturing support; Trenchant plans early access for select partners in 2027 with full commercial release later that year. Executives said the collaboration aims to cut cost‑of‑goods and shorten manufacturing time to make CGTs more scalable and accessible.